Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Clinical trial NCT06645678 · RECRUITING

Trial details

NCT number: NCT06645678
Sponsor: YOUNGIL KOH
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed Refractory Multiple Myeloma (RRMM)

Start date: 2024-11-26
Primary completion: 2026-10-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.